Want to see VTGN full AI Analyst Report?
VistaGen Therapeutics (VTGN) Ratios
1,156 Followers
VistaGen Therapeutics Ratios
VTGN's free cash flow for Q1 2027 was $-14.71M. For the 2027 fiscal year, VTGN's free cash flow was increased by $0.00 and operating cash flow was $-14.71M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.67 | 6.51 | 23.55 | 3.83 | 12.32 |
| Quick Ratio | 3.67 | 6.51 | 23.55 | 3.83 | 12.32 |
| Cash Ratio | 2.41 | 5.32 | 23.26 | 3.64 | 11.82 |
| Solvency Ratio | -5.29 | -3.64 | -3.07 | -6.52 | -4.74 |
| Operating Cash Flow Ratio | -5.19 | -3.34 | -5.04 | -10.87 | -7.85 |
| Short-Term Operating Cash Flow Coverage | -692.04 | 0.00 | 0.00 | -473.49 | 0.00 |
| Net Current Asset Value | $ 33.90M | $ 68.13M | $ 111.31M | $ 8.50M | $ 61.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.02 | 0.13 | 0.04 |
| Debt-to-Equity Ratio | 0.03 | 0.02 | 0.02 | 0.22 | 0.05 |
| Debt-to-Capital Ratio | 0.03 | 0.02 | 0.02 | 0.18 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.37 | 1.20 | 1.08 | 1.75 | 1.15 |
| Debt Service Coverage Ratio | -743.75 | 0.00 | 0.00 | -458.92 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -2576.87 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.05 | 0.11 | 0.39 | 0.46 |
| Net Debt to EBITDA | 0.42 | 1.29 | 3.61 | 0.24 | 1.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -5683.69% | -10578.40% | -3103.48% | 26109.25% | -4306.88% |
| EBITDA Margin | -5625.93% | -10447.74% | -3050.09% | 25874.89% | -4242.75% |
| Operating Profit Margin | -5683.69% | -11517.08% | -3103.48% | 26109.25% | -4308.68% |
| Pretax Profit Margin | -5490.78% | -10578.40% | -2759.21% | 26097.80% | -4306.88% |
| Net Profit Margin | -5491.33% | -10579.84% | -2759.59% | 26100.44% | -4307.19% |
| Continuous Operations Profit Margin | -5491.33% | -10579.84% | -2759.59% | 26100.44% | -4307.19% |
| Net Income Per EBT | 100.01% | 100.01% | 100.01% | 100.01% | 100.01% |
| EBT Per EBIT | 96.61% | 91.85% | 88.91% | 99.96% | 99.96% |
| Return on Assets (ROA) | -143.49% | -60.96% | -23.75% | -280.94% | -63.99% |
| Return on Equity (ROE) | -196.19% | -73.05% | -25.69% | -490.46% | -73.80% |
| Return on Capital Employed (ROCE) | -201.64% | -78.03% | -27.86% | -358.87% | -69.37% |
| Return on Invested Capital (ROIC) | -197.26% | -77.43% | -27.73% | -346.47% | -68.93% |
| Return on Tangible Assets | -143.49% | -60.96% | -23.75% | -280.94% | -63.99% |
| Earnings Yield | -320.25% | -66.61% | -28.09% | -236.50% | -19.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | -0.28 | 0.40 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.03 | 0.27 | 0.47 | -0.08 | 0.36 |
| Asset Turnover | 0.03 | 0.01 | 0.01 | -0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.02 | 0.01 | 0.02 | -0.01 | 0.01 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -1290.69 | 903.79 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | -1290.69 | 903.79 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | -1290.69 | 903.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.74 | -1.36 | -1.33 | -7.14 | -6.86 |
| Free Cash Flow Per Share | -1.74 | -1.37 | -1.34 | -7.17 | -6.89 |
| Dividend Paid and CapEx Coverage Ratio | -439.97 | -220.40 | -423.16 | -234.51 | -0.05 |
| Capital Expenditure Coverage Ratio | -439.97 | -220.40 | -423.16 | -234.51 | -225.83 |
| Operating Cash Flow Coverage Ratio | -63.64 | -27.90 | -12.18 | -18.34 | -14.89 |
| Operating Cash Flow to Sales Ratio | -52.35 | -86.62 | -24.26 | 219.01 | -40.81 |
| Free Cash Flow Yield | -305.32% | -54.78% | -24.76% | -199.30% | -18.52% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.31 | -1.50 | -3.56 | -0.42 | -5.14 |
| Price-to-Sales (P/S) Ratio | 17.15 | 158.83 | 98.23 | -110.36 | 221.38 |
| Price-to-Book (P/B) Ratio | 0.61 | 1.10 | 0.91 | 2.07 | 3.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.33 | -1.83 | -4.04 | -0.50 | -5.40 |
| Price-to-Operating Cash Flow Ratio | -0.33 | -1.83 | -4.05 | -0.50 | -5.42 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | -0.15 | 0.04 | -0.03 | 0.10 |
| Enterprise Value Multiple | 0.11 | -0.23 | 0.39 | -0.19 | -3.83 |
| Enterprise Value | -7.99M | 11.57M | -12.53M | 11.12M | 180.40M |
| EV to EBITDA | 0.11 | -0.23 | 0.39 | -0.19 | -3.83 |
| EV to Sales | -6.29 | 23.81 | -11.78 | -49.01 | 162.68 |
| EV to Free Cash Flow | 0.12 | -0.27 | 0.48 | -0.22 | -3.97 |
| EV to Operating Cash Flow | 0.12 | -0.27 | 0.49 | -0.22 | -3.99 |
| Tangible Book Value Per Share | 0.93 | 2.28 | 5.90 | 1.74 | 9.81 |
| Shareholders’ Equity Per Share | 0.93 | 2.28 | 5.90 | 1.74 | 9.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.03 | 0.02 | 0.05 | -0.03 | 0.17 |
| Net Income Per Share | -1.83 | -1.67 | -1.52 | -8.51 | -7.24 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.97 | 1.00 | 0.89 | 1.00 | 1.00 |
| Research & Development to Revenue | 43.32 | 81.02 | 18.82 | -195.49 | 31.93 |
| SG&A to Revenue | 14.52 | 35.15 | 13.22 | -64.60 | 9.43 |
| Stock-Based Compensation to Revenue | 3.15 | 8.88 | 2.05 | -14.70 | 3.14 |
| Income Quality | 0.95 | 0.82 | 0.88 | 0.84 | 0.95 |
Currency in USD
